ArticleJournal of contemporary brachytherapy2026
Dosimetric evaluation of superficial radionuclide-based high-dose-rate brachytherapy for deep keratinocyte carcinoma: A case series.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Keratinocyte carcinoma (KC) is the most common malignancy in the United States. Current American Brachytherapy Society and GEC-ESTRO guidelines recommend interstitial high-dose-rate (HDR) brachytherapy for tumors exceeding 5 mm in depth. This case series evaluated the feasibility and efficacy of superficial radionuclide-based HDR brachytherapy for deep (> 5 mm) KC. Material and methods: Four patients with pathologically confirmed KC were treated at a single institution between March 2019 and November 2023. All received 40 Gy in 8 fractions, delivered twice weekly. Three patients with deeper lesions were treated using a custom, in-house multichannel flap applicator, with a 1 cm source-to-skin distance to achieve adequate dose at depth while minimizing V Results: The median patient age was 90.2 years (range, 81-95), and the median tumor depth was 7.6 mm (range, 5.6-10.8). The median V Conclusions: Superficial radionuclide-based HDR brachytherapy is a safe and feasible modality for treating deep (> 5 mm) KC. A 1 cm source-to-skin distance applicator optimizes dose distribution for thicker lesions while maintaining acceptable toxicity and cosmesis. Further prospective studies are warranted to validate long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.